Immuneering Corp
IMRX9.010USD
+0.940+11.65%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
324.25MMarket Cap
LossP/E TTM
More Details of Immuneering Corp Company
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Company Info
Ticker SymbolIMRX
Company nameImmuneering Corp
IPO dateJul 30, 2021
CEODr. Benjamin J. (Ben) Zeskind, Ph.D.
Number of employees66
Security typeOrdinary Share
Fiscal year-endJul 30
Address245 Main Street, Second Floor
CityCAMBRIDGE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02142
Phone16175008080
Websitehttps://immuneering.com/
Ticker SymbolIMRX
IPO dateJul 30, 2021
CEODr. Benjamin J. (Ben) Zeskind, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.21M
+0.31%
Mr. Robert J. Carpenter
Mr. Robert J. Carpenter
Independent Director
Independent Director
1.15M
--
Ms. Ann E. Berman, CPA
Ms. Ann E. Berman, CPA
Independent Chairman of the Board
Independent Chairman of the Board
67.47K
--
Dr. Thomas J. Schall, Ph.D.
Dr. Thomas J. Schall, Ph.D.
Independent Director
Independent Director
52.88K
+1723.62%
Ms. Mallory Morales
Ms. Mallory Morales
Chief Accounting Officer, Treasurer
Chief Accounting Officer, Treasurer
27.23K
+113.83%
Ms. Leah R. Neufeld
Ms. Leah R. Neufeld
Chief People Officer
Chief People Officer
22.54K
+110.12%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Director
Independent Director
14.00K
--
Dr. Igor Matushansky, M.D., Ph.D.
Dr. Igor Matushansky, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Diana F. Hausman, M.D.
Dr. Diana F. Hausman, M.D.
Independent Director
Independent Director
--
--
Mr. Michael D. Bookman
Mr. Michael D. Bookman
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.21M
+0.31%
Mr. Robert J. Carpenter
Mr. Robert J. Carpenter
Independent Director
Independent Director
1.15M
--
Ms. Ann E. Berman, CPA
Ms. Ann E. Berman, CPA
Independent Chairman of the Board
Independent Chairman of the Board
67.47K
--
Dr. Thomas J. Schall, Ph.D.
Dr. Thomas J. Schall, Ph.D.
Independent Director
Independent Director
52.88K
+1723.62%
Ms. Mallory Morales
Ms. Mallory Morales
Chief Accounting Officer, Treasurer
Chief Accounting Officer, Treasurer
27.23K
+113.83%
Ms. Leah R. Neufeld
Ms. Leah R. Neufeld
Chief People Officer
Chief People Officer
22.54K
+110.12%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Zeskind (Benjamin J)
7.72%
Merrin Investors, L.L.C.
6.66%
Carpenter (Robert J)
2.76%
Feinberg (Peter)
2.70%
The Vanguard Group, Inc.
2.54%
Other
77.62%
Shareholders
Shareholders
Proportion
Zeskind (Benjamin J)
7.72%
Merrin Investors, L.L.C.
6.66%
Carpenter (Robert J)
2.76%
Feinberg (Peter)
2.70%
The Vanguard Group, Inc.
2.54%
Other
77.62%
Shareholder Types
Shareholders
Proportion
Individual Investor
14.55%
Corporation
6.66%
Investment Advisor
5.63%
Investment Advisor/Hedge Fund
2.50%
Hedge Fund
0.91%
Research Firm
0.18%
Venture Capital
0.06%
Other
69.50%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
159
13.40M
37.24%
-6.12M
2025Q1
161
13.19M
41.31%
-6.04M
2024Q4
164
13.00M
41.85%
-6.73M
2024Q3
162
13.05M
42.83%
-8.70M
2024Q2
161
18.30M
60.87%
-2.07M
2024Q1
151
20.58M
69.02%
-6.37M
2023Q4
145
24.26M
82.88%
-4.62M
2023Q3
147
25.15M
85.99%
-3.63M
2023Q2
142
25.50M
87.18%
+568.32K
2023Q1
129
20.04M
76.48%
+592.90K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Zeskind (Benjamin J)
3.20M
8.89%
+21.00K
+0.66%
Jun 18, 2025
Merrin Investors, L.L.C.
2.77M
7.7%
--
--
Apr 17, 2025
Carpenter (Robert J)
1.15M
3.19%
--
--
Apr 17, 2025
Feinberg (Peter)
1.12M
3.12%
+25.00K
+2.28%
Jun 18, 2025
The Vanguard Group, Inc.
1.06M
2.94%
--
--
Mar 31, 2025
Marshall Wace LLP
807.97K
2.25%
+786.54K
+3669.92%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
311.91K
0.87%
-1.03K
-0.33%
Mar 31, 2025
Hall (Brett Matthew)
359.32K
1%
+13.42K
+3.88%
Jun 23, 2025
Southport Management, L.L.C.
245.00K
0.68%
+30.00K
+13.95%
Mar 31, 2025
Geode Capital Management, L.L.C.
225.82K
0.63%
+17.43K
+8.36%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
